Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis

This study has been terminated.
(The study treminated early according to DSMB recommendantions)
Information provided by (Responsible Party):
Federation Francophone de Cancerologie Digestive Identifier:
First received: March 2, 2010
Last updated: March 3, 2014
Last verified: March 2010

RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase II trial is studying how well temsirolimus works in treating patients with advanced liver cancer and cirrhosis.

Condition Intervention Phase
Liver Cancer
Drug: temsirolimus
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Advanced Hepatocellular Carcinoma on Child B Cirrhosis: Tolerance and Efficacy of Torisel® (Temsirolimus)

Resource links provided by NLM:

Further study details as provided by Federation Francophone de Cancerologie Digestive:

Primary Outcome Measures:
  • 3-month disease-control rate according to RECIST criteria [ Time Frame: 2010 ]

Secondary Outcome Measures:
  • 3-month objective response rate according to RECIST criteria [ Time Frame: 2010 ]

Enrollment: 6
Study Start Date: January 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Drug: temsirolimus

Detailed Description:



  • To determine the 3-month disease-control rate according to RECIST criteria in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis.


  • To determine the 3-month objective response rate according to RECIST criteria in these patients.
  • To determine the 1-month metabolic response rate on PET/CT scan in these patients.
  • To determine the 1-month perfusion response rate on hepatic perfusion CT scan in these patients.
  • To determine the time to progression in patients treated with this drug.
  • To determine the progression-free survival of patients treated with this drug.
  • To determine the overall survival of patients treated with this drug.
  • To assess quality of life according to QLQ-C30 and QLQ-HCC18 questionnaires.
  • To determine the clinical and biological tolerance of this drug in these patients.
  • To determine the rate of m-TOR pathway activation and VEGF level.
  • To evaluate the pharmacokinetics of this drug in select patients.

OUTLINE: This is a multicenter study.

Patients receive temsirolimus IV over 30-60 minutes on day 1. Treatment repeats once a week in the absence of disease progression or unacceptable toxicity. Patients also undergo fludeoxyglucose F 18 (FDG) positron emission tomography/computed tomography (PET/CT) scan and perfusion CT scan of the liver at baseline and periodically during study treatment.

Patients complete quality of life questionnaires (QLC-C30 and QLQ-HCC18) periodically. Some patients undergo blood and tissue sample collection periodically for pharmacological and laboratory studies.

After completion of study therapy, patients are followed for up to 24 months.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Diagnosis of hepatocellular carcinoma (HCC) according to the European Association for the Study of the Liver (EASL) criteria

    • Advanced disease
    • Must be morphologically evaluable
  • HCC not accessible to other treatment (e.g., surgery, radiofrequency, or chemoembolization) and can not benefit from antiangiogenic therapy
  • CLIP score ≤ 3 (except for patients with tumors invading more than 50% of tumor volume)
  • Child-Pugh cirrhosis score between B7 and B9, meeting the following criteria:

    • Diagnosed clinically, biologically (e.g., prothrombin time, platelets, or albumin), endoscopically (signs of portal hypertension) and morphologically (dysmorphic liver on ultrasound or CT scan), or by liver biopsy
  • Not a candidate for transplantation and has not received a liver transplant


  • ECOG performance status 0-2
  • Life expectancy ≥ 3 months
  • Platelet count ≥ 50,000/mm^3
  • Neutrophil count ≥ 1,500/mm^3
  • Creatinine clearance ≥ 60 mL/min
  • GFR ≥ 30 mL/min
  • Serum cholesterol ≤ 350 mg/dL
  • Triglycerides ≤ 300 mg/dL
  • Not pregnant or nursing
  • Fertile patients must use effective contraception during and for more than 2 months after completion of study therapy
  • No history of other cancer on treatment
  • No cardiopulmonary disease impairment, including a history of stable or unstable angina or myocardial infarction
  • No active infection except for viral hepatitis
  • No HIV positivity


  • See Disease Characteristics
  • At least 2 weeks since prior inhibitors or inducers of P-glycoprotein, CYP3A4, or CYP3A5
  • At least 4 weeks since prior surgery, radiotherapy (except radiotherapy to the bone), transarterial chemoembolization, immunotherapy, or other investigational drug for HCC
  • At least 6 months since prior chemotherapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01079767

Centre Hospitalier Universitaire Henri Mondor
Creteil, France, 94010
Sponsors and Collaborators
Federation Francophone de Cancerologie Digestive
Principal Investigator: Thomas Decaens, MD Centre Hospitalier Universitaire Henri Mondor
Principal Investigator: Christophe Duvoux Centre Hospitalier Universitaire Henri Mondor
  More Information

Responsible Party: Federation Francophone de Cancerologie Digestive Identifier: NCT01079767     History of Changes
Other Study ID Numbers: CDR0000666229
Study First Received: March 2, 2010
Last Updated: March 3, 2014

Keywords provided by Federation Francophone de Cancerologie Digestive:
adult primary hepatocellular carcinoma
advanced adult primary liver cancer
localized unresectable adult primary liver cancer
recurrent adult primary liver cancer

Additional relevant MeSH terms:
Carcinoma, Hepatocellular
Liver Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents processed this record on May 25, 2017